No Data
Reported Wednesday, HUTCHMED And AstraZeneca's ORPATHYS-TAGRISSO Therapy Advances In China With Priority NDA Status For MET-Amplified Lung Cancer
China's Medical Regulator Accepts for Priority Review Hutchmed's Lung Cancer Treatment Application
Hutchmed Projects Gain of $477 Million From Hutchison Pharmaceutical Stake Disposal
Market Update | Hutchmed (China) rises nearly 10%, with the new drug combination for lung cancer treatment application accepted by the National Medical Products Administration and prioritized for review.
Hutchmed (China) rose nearly 10%. As of the time of publication, it is up 9.76%, priced at 24.75 Hong Kong dollars, with a trading volume of 0.2 billion Hong Kong dollars.
Hutchmed (China) (00013.HK) rose over 7% in early trading, selling its stake in Shanghai Hutchmed Pharmaceuticals for 4.5 billion yuan.
Hutchmed (China) (00013.HK) opened today (2nd) with a rise of 3.1%, and the increase expanded, reaching a high of 24.4 yuan. Currently, it is reported at 24.2 yuan, up 7.32%, with a trading volume of 5.3285 million shares, involving 0.127 billion yuan. Hutchmed (China) has signed agreements with SH PHARMA (02607.HK) and Jinfuhuan, selling 10% and 35% equity stakes in Shanghai Hutchmed Pharmaceutical, respectively, cashing out a total of 4.48 billion yuan. Hutchmed (China) stated that after the Trade is completed, it will further optimize the group's capital and debt structure, and allow the group to concentrate its resources on its core Business areas. In addition, Hutchmed (China) announced that Worui
[Hong Kong Stock Connect] Hutchmed (China) (00013) rose 5.76% against the market trend as the company's new lung cancer drug application was approved and granted priority review.
Jingu Financial News | Hutchmed (China) (00013) rose against the market trend at the beginning of trading, as of press time, it was up 5.76%, trading at HKD 23.85, with a turnover of HKD 94.2265 million. The company announced that the combination therapy of orpathys (savolitinib) and tagrisso (osimertinib) is used to treat EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who progress after first-line epidermal growth factor receptor (EGFR) inhibitor treatment with MET amplification.
